Target
Programmed cell death protein 1 (PD-1)
199 abstracts
Abstract
Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labeled, phase Ib study.Org: Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, West China Hospital, Sichuan University,
Abstract
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,
Abstract
A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,
Abstract
Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.Org: University of Pittsburgh Medical Center Hillman Cancer Center, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Aichi Cancer Center Hospital, Memorial Sloan Kettering Cancer Center, University of Ulsan College of Medicine,
Abstract
Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.Org: Massachusetts General Hospital, Department of Experimental Therapeutics, National Cancer Center Hospital East, National Cancer Center Hospital East, Kashiwa, Japan, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Memorial Sloan Kettering Cancer Center,
Abstract
A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability.Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Illumina Inc., Fortrea Inc.,
Abstract
Endogenous retrotransposable elements as a novel predictive biomarker of response to immunotherapy.Org: Princess Alexandra Hospital & University of CanadaQueensland,
Abstract
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3).Org: UTEC Hospital Clínico San Carlos, START Madrid - CIOCC, Waltham,
Abstract
Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,
Abstract
A pilot study of early PET and biomarker dynamics in patients with stage 2 and 3 triple negative breast cancer treated with neoadjuvant response-adapted chemotherapy with pembrolizumab (NeoADAPT).Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Radiology at Johns Hopkins,
Abstract
Safety and preliminary efficacy of EIK1001 in combination with atezolizumab in participants with advanced solid tumors.Org: Eikon Therapeutics, Inc.,
Abstract
Health-related quality of life (HRQoL) and symptoms in LIBRETTO-431 patients with RET fusion-positive advanced non-small-cell lung cancer (NSCLC).Org: Shanghai Pulmonary Hospital, Shanghai, China, AOU San Luigi, University of Torino, Hospital Ramón y Cajal, University Hospitals KU Leuven,
Abstract
NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).Org: University of Kansas Medical Center, ZAS Hospitals, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, University of Kansas Cancer Center,
Abstract
Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.Org: HonorHealth Research and Innovation Institute, Center for Cancer and Blood Disorders, Med Onc / Hem Consultants,
Abstract
Evaluating gut microbiome as a biomarker of pathological complete response in patients with early locally advanced triple negative breast cancer (LA TNBC): A pilot study.Org: H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, MCC Physicians, Duke University Medical Center, Duke Cancer Institute,
Abstract
Patient-reported experience with an immunotherapy telehealth platform.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University,
Abstract
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.Org: Hematology Oncology Association of the Treasure Coast,
Abstract
A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.Org: Division of Hematology/Oncology, University of Cincinnati Cancer Center,
Abstract
A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors.Org: NextGen Oncology,
Abstract
Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.Org: Duke University Medical Center, Durham, NC, Personalis, Inc., Menlo Park, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Informing optimal treatment (tx) sequences for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States: Results of a clinical simulation modeling exercise.Org: Evidera, Inc, EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA,
Abstract
Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).Org: IRCCS San Raffaele Hospital and Scientific Institute, Division of Hematology/Oncology, UCLA David Geffen School of Medicine,
Abstract
Sintilimab plus axitinib for advanced fumarate hydratase-deficient renal cell carcinoma: A multi-center, open-label, single-arm, phase II study (SAFH).Org: Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, West China Hospital, Sichuan University, Chengdu, Sichuan, China, Department of Radiology, West China Hospital, Sichuan University, Chengdu, China, Department of Urology, Southwest Hospital, Army Medical University, Chongqing, Chengdu, China, The First Affiliated Hospital of Kunming Medical University, Kunming, China,
Abstract
Preoperative nivolumab plus SOX in patients with locally advanced gastric or gastro-esophageal junction cancer: A phase 2, single-arm trial.Org: Department of Gastric Surgery, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences,
Abstract
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up.Org: Maria Sklodowska-Curie National Cancer Research Institute,
Abstract
Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.Org: Kaiser Permanente San Diego, Kaiser Permanente National Drug Use Management,
Abstract
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.Org: Winship Cancer Institute of Emory University, Atlanta, GA, University of Alabama at Birmingham, Birmingham, AL, University of California, San Francisco, San Francisco, CA, University of California, San Diego, La Jolla, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA,
Abstract
A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.Org: University Paris Saclay,
Abstract
Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.Org: University Hospitals Case Medical Center, Piedmont Cancer Institute, P.C.,
Abstract
Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).Org: Liver Cancer Institute, Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Department of Hepatic Surgery V, Center of Hepato-Pancreato-Biliary Surgery,
Abstract
Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).Org: Amsterdam UMC, University of Amsterdam, ENETS Center of Excellence, Cancer Center Amsterdam, Charite Campus Charite Mitte,
Abstract
A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE).Org: Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD, Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, Urologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD,
Abstract
Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.Org: National Clinical Research Centre for Cancer,
Abstract
Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma.Org: Stanford Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,
Abstract
Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).Org: Mayo Clinic, Stanford University Medical Center, Stanford, CA,
Abstract
Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma.Org: IEO European Institute of Oncology IRCCS, Merck and Co Inc Kenilworth,
Abstract
Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy.Org: University of Florida Department of Surgery, University of Florida College of Public Health and Health Professions, University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy,
Abstract
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma (nccRR): Preliminary results from an exploratory prospective multicentre clinical study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer.Org: Cancer Vaccine Institute, UW Medicine, Precigen, Inc.,
Abstract
Hepatic artery infusion chemotherapy (HAIC) combined with tislelizumab and lenvatinib for initial unresectable hepatocellular carcinoma (HCC) with portal vein tumor thrombus: A prospective, single-arm phase II trial.Org: The First Affiliated Hospital of Chongqing Medical University,
Abstract
A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.Org: University of Texas Southwestern Medical School, The University of Chicago Medicine Comprehensive Cancer Center, The University of Edinburgh, Cancer Research UK Beatson Institute, CR-UK Beatson Institute & MRC Centre for Inflammation Research,
Abstract
Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.Org: University of Michigan Rogel Cancer Center, University of Chicago, Dana-Farber Cancer Institute, University of Wisconsin, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.Org: IDIBELL Medical Oncology,
Abstract
Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.Org: Jiangmen, China,
Abstract
Cost effectiveness analysis of nadofaragene firadenovec for the treatment of high-risk, bacillus Calmette-Guerin–unresponsive, non-muscle invasive bladder cancer from a US third-party payer perspective.Org: Analysis Group Inc.,
Abstract
Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.Org: The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,
Abstract
Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma.Org: Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,
Abstract
Tumor-derived serum proteotypes to predict response to immune therapy in patients with limited disease small-cell lung cancer.Org: Frontier Science Foundation - Hellas, Hospital Virgen De La Salud, Hôpital Arnaud de Villeneuve, St. James's Hospital and Trinity College Dublin, Cancer Molecular Diagnostics,
Abstract
A randomized phase II study of toripalimab consolidation or observation after concurrent chemoradiotherapy in limited-stage small cell lung cancer.Org: Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China, Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China, Sun Yat-Sen University Cancer Center, Guangzhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.Org: NCIC Clinical Trials Group,
Abstract
Comparative analysis of Keynote522 treatment outcomes in Hispanic versus non-Hispanic patients with breast cancer: A single tertiary center experience.Org: Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health and Science Center at San Antonio,
Abstract
Phase Ib study of a high potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced solid tumors.Org: Department of Gynecologic Oncology, Gynecology and Obstetrics Center, The First Hospital of Jilin University, Changchun, China, Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, China, The First Hospital of Jilin University, Changchun, Jilin Province, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, Shanghai, China, Shanghai Jiatan Pharmatech CO., LTD., Shanghai, China,
Abstract
Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: Retrospective analysis from a tertiary care center.Org: Chardon, OH, Cancer Informatics,
Abstract
LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer.Org: Franciscan Health Indianapolis,
Abstract
Evaluation of the immune landscape associated with the efficacy of immunotherapy in patients with triple-negative breast cancer: Starlet study, synergy between research and clinical work.Org: Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy, Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Breast Surgery Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy,
Abstract
Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC).Org: Zucker School of Medicine,
Abstract
PD-1 inhibitor combined with ablation in liver metastasis: A retrospective, multicenter study.Org: Sun Yat-sen University Cancer Center Gansu Hospital, The First Affiliated Hospital of Zhengzhou University, Cancer Hospital Affiliated to Xinjiang Medical University,
Abstract
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,
Abstract
Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.Org: Memorial Sloan Kettering Cancer Center, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, Breast Service, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,
Abstract
Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.Org: A.C. Camargo Cancer Center, São Paulo, Brazil,
Abstract
Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.Org: Yamaguchi University Hospital, Fundación Arturo López Pérez, Fred Hutchinson Cancer Center and University of Washington, Life Groenkloof Hospital, Istinye University Liv Hospital,
Abstract
Osimertinib related cardiotoxicity in patients with non-small cell lung cancer.Org: West Virginia University Camden Clark Medical Center, Morgantown, WVU Camden Clark Medical Center,
Abstract
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, IRCCS San Raffaele Hospital, Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele,
Abstract
Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.Org: Hospital 9 de Julho, Hospital Santa Paula, Clínica AMO, Instituto do Câncer do Ceara,
Abstract
Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.Org: Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan, Department of Gastroenterological and Pediatric Surgery, Gifu University Hospital, Gifu-Shi, Japan, Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-Shi, Japan,
Abstract
Retro TIMing: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma.Org: Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, Unidade Local de Saúde de Santo António,
Abstract
The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.Org: Inst for Clinical Evaluative Sci,
Abstract
A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.Org: Merck & Co., Inc., Gustave Roussy Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yale University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,
Abstract
Preoperative (neoadjuvant) therapy with tislelizumab for locally advanced colorectal cancer with high microsatellite instability or deficient mismatch repair: An open-label, single-arm, multicenter phase II study.Org: The Second Affiliated Hospital of Zhejiang University School of Medicine,
Abstract
Effectiveness and safety of first-line serplulimab in patients with metastatic/locally advanced esophageal carcinoma (EC): A real-world study.Org: Subei People's Hospital of Jiangsu Province, Taizhou People's Hospital,
Abstract
Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.Org: Massey Comprehensive Cancer Center, Division of Hematology, Oncology, and Palliative Care,
Abstract
Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study.Org: Hefei, China,
Abstract
Real-world treatment patterns and outcomes of patients with advanced melanoma treated with nivolumab plus relatimab.Org: Georgetown University School of Medicine,
Abstract
Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.Org: University of Texas Medical Branch at Galveston, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.Org: Montgomery Regional Medical Campus,
Abstract
Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,
Abstract
A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.Org: Fujian Cancer Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, West China Hospital, Union Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,
Abstract
Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,
Abstract
Efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Union Hospital, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital,
Abstract
Health outcomes of pembrolizumab plus chemotherapy in non-small cell lung cancer.Org: Jaén, Spain, Jaen, Spain,
Abstract
Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.Org: Owkin France, Centre Leon Berad,
Abstract
TACE combined with tislelizumab and lenvatinib in the treatment of advanced liver cancer: A real world study.Org: Department of General Surgery (Hepatopancreatobiliary Surgery), Affiliated Hospital of Southwest Medical University, Luzhou, The Affiliated Hospital of Southwest Medical University, Luzhou,
Abstract
Efficacy and safety of donafenib combined with anti-PD-1 antibodies for initially unresectable hepatocellular carcinoma (HCC): A retrospective real-world study.Org: People's Hospital of Hunan Province,
Abstract
Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,
Abstract
Sugemalimab in locally advanced and advanced Chinese NSCLC: A real-world retrospective study.Org: Department of Medical Oncology, National Cancer Center / National Clinical Research Center for Cancer / Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China, Department of Medical Oncology, Beijing Chaoyang Sanhuan Cancer Hospital, Beijing, Beijing, China, Department of Medical Oncology, Cancer Hospital of HuanXing, ChaoYang District, Beijing, Beijing, China, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China,
Abstract
Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study.Org: Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Department of Urology, Xiangya Hospital Central South Universiity, Department of Urology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,
Abstract
PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,
Abstract
Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,
Abstract
Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.Org: University of Kansas Cancer Center, GZA ANTWERP BELGIUM, Texas Oncology, University of Kansas Medical Center, University of Kansas Medical Center Department of Internal Medicine,
Abstract
Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.Org: Laura and Isaac Perlmutter Cancer Center, Sir Charles Gairdner Hospital, Washington University Oncology, Sarah Cannon Research Institute/Tennessee Oncology, One Clinical Research and Edith Cowan University,
Abstract
IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.Org: Cross Cancer Institute, Assistance Publique Hôpitaux de Marseille (AP-HM), Fondazione IRCCS Istituto Nazionale Tumori, AZ Ospedaliera Villa Scassi, National Cancer Institute of Naples,
Abstract
A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.Org: University of Pennsylvania, Abramson Cancer Center, Penn Presbyterian Medical Center, Perelman School of Medicine,
Abstract
Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018.Org: Department of Gynecology, Gunma Prefectural Cancer Center, Ota, Japan, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka, Japan, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, Department of Obstetrics and Gynecology, Jichi Medical University, Shimotsuke, Japan, Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan,
Abstract
EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).Org: University of Southern California Marshall School of Business, Vasgene Therapeutics, Inc, Rutgers University, Dana-Farber Cancer Institute, University of Colorado Cancer Center Anschutz Medical Campus,
Abstract
Targeting minimal residual disease (MRD) in resected RAS mutated pancreatic cancer with vaccine TG01/QS-21 +/- PD-1 inhibitor, balstilimab: A randomized phase II study (TESLA).Org: University of Kansas Cancer Center, Kansas City, KS, University of Kansas Medical Center (KUMC), University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC).Org: Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Hackensack Meridian Health, MedStar Washington Hospital Center,
Abstract
NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).Org: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong, National Cancer Center of Singapore, Singapore, Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, Hong Kong, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong,
Abstract
Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).Org: Massachusetts General Hospital, Stanford Medical Center,
Abstract
A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.Org: University of Chicago, University of Texas MD Anderson Cancer Center, Department of Hematology Oncology University of Illinois of Chicago College of Medicine, UPMC Hillman Cancer Center, University of Illinois Urbana-Champaign,
Abstract
A phase 2 randomized, open-label, multicentre study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.Org: Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Chinese Academy of Sciences, Zhejiang Cancer Hospital, Chinese Academy of Sciences,
Abstract
The study of immune-related adverse events in a community-based centre.Org: BronxCare Health System, Bronx-Lebanon Hospital Center, BronxCare Mount Sinai Comprehensive Cancer Care,
Abstract
Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,
Abstract
The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.Org: Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Barbara Ann Karmanos Cancer Institute, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center,
Abstract
Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.Org: Early Phase Clinical Trials Unit, START Madrid Fundacion Jimenez Diaz, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), University College London Hospital NHS Trust and Great Ormond Street Hospital,
Abstract
Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Erasmus University Rotterdam, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Amphia Hospital, Cancer Center Amsterdam,
Abstract
Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.Org: University of Chicago, UPMC Hillman Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,
Abstract
The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust, Taipei TzuChi Hospital,
Abstract
Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.Org: Roswell Park Comprehensive Cancer Center, Buffalo, IL, Nykode Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital,
Abstract
The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer.Org: IRCCS Ospedale Policlinico San Martino, Sant’Orsola Malpighi Hospital, University of Bologna,
Abstract
Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.Org: Centre Leon Berard, Lyon I University, Hôpital Européen Georges Pompidou, Sorbonne University and Saint-Antoine Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Melanomas lacking HLA class I expression and response to checkpoint inhibitor.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.Org: Roswell Park Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Institute, University Hospitals, Case Comprehensive Cancer Center, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Catholic Health Systems,
Abstract
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.Org: Washington University School of Medicine in St Louis, Natco Pharma, NATCO Pharma Limited,
Abstract
Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in head and neck cancer (HNSCC) patients.Org: H. Lee Moffitt Cancer Center and Research Institute, Duke Medical Center, Moffitt Cancer Center, Advent Health, University of South Florida Morsani College of Medicine,
Abstract
Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.Org: Carolina BioOncology Institute, Massachusetts General Hospital, Hackensack Meridian Health, Moderna Therapeutics, Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,
Abstract
Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).Org: King's College London, Guy's and St. Thomas' NHS Foundation Trust, Guy's and St. Thomas' Hospital, Guys' and St. Thomas' NHS Foundation Trust,
Abstract
Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).Org: Huntsman Cancer Institute at the University of Utah, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, BC Cancer Agency Vancouver Island Centre, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada,
Abstract
Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).Org: BeiGene (USA) Co., Ltd., BeiGene (Beijing) Co., Ltd., Beijing, China, BeiGene Co., Ltd., Jiahui Cancer Center, Massachusetts General Hospital,
Abstract
Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.Org: The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center,
Abstract
Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.Org: Yonsei University College of Medicine, Severance Hospital, SMT Bio, SMT bio Co.Ltd,
Abstract
Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.Org: Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Brigham and Women’s Hospital, Harvard Medical School, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University of California Davis Comprehensive Cancer Center,
Abstract
CheMo4METPANC: A phase 2 study with combination chemotherapy (gemcitabine and nab-paclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in metastatic treatment-naïve pancreas adenocarcinoma.Org: Columbia University Medical Center/New York-Presbyterian Hospital, Columbia University Medical Center, Columbia University - Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, USA, Columbia University Herbert Irving Comprehensive Cancer Center,
Abstract
First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.Org: Memorial Sloan Kettering Cancer Center, Macquarie University, Volga District Medical Center, Federal Medical-Biological Agency, Medical Oncology Group,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
TROP2 expression and response to immune checkpoint inhibition in patients with advanced non-small cell lung cancer.Org: Early Phase Trials Unit, Institut Bergonié and University of Bordeaux, Bordeaux, France, Institut Bergonié, University of Bordeaux, Bergonié Institute, ImmuSmol,
Abstract
TCR-T cells armored with immune checkpoint blockade in EBV-positive nasopharyngeal carcinoma: The first-in-human phase 1/2 trial.Org: Institute of Cancer, Xinqiao Hospital, Chongqing, China, Guangdong TCRCure Biopharma Technology Co., Ltd, Guangzhou, China, Biomedical Analysis Center, Chongqing, China, TCRCure Biopharma Corp., Los Angeles, CA, Institute of Molecular and Cell biology & Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore,
Abstract
Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.Org: Rush University Medical Center, Natera, Inc.,
Abstract
A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,
Abstract
Analysis of overall survival (OS) and progression-free survival (PFS) in the phase 1b clinical trial of anti–PD-1 ab (toripalimab) plus intrahepatic injection of OrienX010 in stage IV melanoma with liver metastases.Org: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma Oncology, Peking University Cancer Hospital & Institute, Department of Renal Cancer and Melanoma, Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,
Abstract
ABC-12: Exploring the microbiome in patients (pts) with advanced biliary tract cancer (BTC) in a first-line study of durvalumab in combination with cisplatin/gemcitabine (cis/gem).Org: University of Manchester/The Christie NHS Foundation Trust, Manchester, United Kingdom, Cardiff University School of Medicine, Cardiff, United Kingdom, The Christie and Salford Royal Hospital NHS Foundation Trusts,
Abstract
Peripheral myeloid cells as prognostic markers in patients (pts) with non-small cell lung cancer (NSCLC) treated with cemiplimab: Pooled analysis of EMPOWER-Lung 1 and EMPOWER-Lung 3 phase 3 trials.Org: Johns Hopkins Kimmel Cancer Center, Regeneron Pharmaceuticals, Inc., Department of Nuclear Medicine Zürich, University Hospital of Zürich, Department of Medical Oncology, Başkent University, High Technology Medical Centre, University Clinic,
Abstract
A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.Org: A.C. Camargo Cancer Center, Hospital de Amor de Barretos, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Liga Norte Riograndense Contra o Câncer, Centro Regional Integrado de Oncologia (CRIO),
Abstract
Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).Org: Duke Cancer Institute, Duke University Medical Center, Barbara Ann Karmanos Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, AdventHealth Cancer Institute, Orlando, FL,
Abstract
Identification of prognostic tumor microenvironment in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy in combination with lenvatinib and PD-1 inhibitors.Org: The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, Department of Minimally Invasive Interventional Therapy, Sun Yat-sen University Cancer Center, Sun Yat-sen University State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Genecast Biotechnology Co., Ltd, Beijing, China,
Abstract
Incidence of venous thromboembolism with immune checkpoint inhibitors in a community setting: A single-center retrospective study.Org: Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Cancer and Wellness Center,
Abstract
Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center,
Abstract
Immune checkpoint inhibition in locally advanced rectal adenocarcinoma at Mayo Clinic.Org: Mayo Clinic, Jacksonville, FL,
Abstract
Real-world impact of oncology education on clinical practices at five community cancer care centers.Org: RMEI Medical Education, LLC, Lineberger Comprehensive Cancer Center, University of North Carolina,
Abstract
Design, reporting, and disparities of advanced non–small cell lung cancer phase 3 clinical trials in the era of immunotherapy.Org: Universidade Federal do Parana, Santa Casa de São Paulo School of Medical Sciences, Kingston Health Sciences Center,
Abstract
Immunotherapy-related toxicities: A retrospective analysis of barriers to prompt detection and initiation of treatment in renal cell carcinoma.Org: TCU School of Medicine, UTSW Harold C Simmons Comprehensive Cancer Center,
Abstract
The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.Org: Princess Margaret Cancer Centre, ICES, Ontario Health (Cancer Care Ontario), Princess Margaret - University Health Network, University Health Network,
Abstract
Toxicity and outcomes of ipilimumab plus nivolumab in patients 80 years and older.Org: Mayo Clinic in Arizona, Phoenix Tissue Repair, Azidus Brasil, Mayo Clinic Arizona, Phoenix, AZ, Scottsdale,
Abstract
Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.Org: Max Super Speciality Hospital, Aster Mims Calicut, Malabar Cancer Centre, Regency Hospital, Bombay Hospital,
Abstract
Efficacy and safety in unresectable hepatocellular carcinoma with VP4 tumor embolus using sinilimab plus bevacizumab: A retrospective analysis of real-world evidence.Org: Senior Department of Hepatology, 5th Medical Center of the PLA General Hospital, Peking University 302 Clinical Medical School, The Fifth School of Clinical Medicine, Anhui Medical University,
Abstract
Different efficacy of pembrolizumab in overall survival between Asians and non-Asians with advanced cancers: A systematic review and meta-regression analysis.Org: National Taiwan University Hospital Yunlin Branch, National Taiwan University Cancer Center/Hospital,
Abstract
Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.Org: Beaumont RCSI Cancer Center, Vanderbilt University Medical Center, ConcertAI, Bristol Myers Squibb, Bristol-Myers Squibb,
Abstract
Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.Org: Desert Surgical Oncology, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Castle Biosciences, Castle Biosciences, Inc.,
Abstract
Carboplatin beyond 4 cycles during therapy with carboplatin, pemetrexed, and pembrolizumab for advanced non-small cell lung cancer (NSCLC).Org: Morsani College of Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, Moffitt Cancer Center,
Abstract
The association between body mass index and immune checkpoint inhibitors outcomes in melanoma: Results from real-world data.Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Seidman Cancer Center,
Abstract
Anlotinib combined with sintilimab as first-line treatment in patients with advanced non-clear cell renal cell carcinoma: Preliminary results from an exploratory prospective clinical study.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,
Abstract
Donafenib combined with camrelizumab and transarterial chemoembolization (TACE) as conversion therapy for unresectable hepatocellular carcinoma (uHCC): A prospective, single-arm, phase II study.Org: Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, China, Department of Radiology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China, Department of Pathology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, China, Nanjing, Jiangsu, China, Department of Radiology, Nanjing Drum Tower Hospital, Th...,
Abstract
Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Moffitt Cancer Center and Research Institute, Tampa, FL, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, The Univ of Utah, Salt Lake City, UT,
Abstract
Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.Org: Care Across,
Abstract
Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in adults aged older than 75 years.Org: Kansai Medical University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, National Cancer Center Hospital East, Kashiwa, Japan, Kitasato Daigaku Igakubu, Sagamihara-Shi Minami-Ku, Japan,
Abstract
Immune-related hypophysitis: An analysis of a heterogeneous entity.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,
Abstract
Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.Org: School of Medicine, Nankai University, Tianjin, China, Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Beijing, China, Department of Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing, China, Department of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China,
Abstract
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.Org: Duke University Hospital, Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Health System,
Abstract
A phase 2 study of modified chemotherapy plus pembrolizumab as perioperative therapy for stage II/IIIA esophageal squamous cell carcinoma.Org: The First Medical Center of PLA General Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, General Hospital of Chinese PLA, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital,
Abstract
Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.Org: Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Mount Auburn Hospital, Harvard Medical School, Lahey Hospital and Medical Center, Burlington, MA,
Abstract
Whole genome sequencing for more accurate TMB and mutational signatures in common cancers.Org: Genome Insight Inc., Ajou University School of Medicine, Genome Insight, San Diego, CA, Seoul National University College of Medicine, Seoul National University Hospital,
Abstract
Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma.Org: The Third Affiliated Hospital of Soochow University, Changzhou, China, Changzhou Qianhong Bio-pharma, China National Biotec Group, Medical Department, 3D Medicines Inc.,
Abstract
Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.Org: UC Irvine, University of California Irvine, UCI Health,
Abstract
Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).Org: Memorial Sloan Kettering Cancer Center,
Abstract
A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.Org: Centre for Cancer Biomarkers CCBIO, University of Bergen, Dept. of Urology, Haukeland University Hospital, Dept. of Pathology,
Abstract
Evaluating patient adherence and persistence to first-line tyrosine-kinase inhibitors for metastatic renal cell carcinoma.Org: UCI Medical Center, Hoag Family Cancer Institute and University of Southern California, University of California Irvine, Pfizer, Pfizer Inc., London, United Kingdom,
Abstract
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.Org: US Biotest,
Abstract
Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study.Org: The Fifth Affiliated Hospital of Wenzhou Medical College, Lishui, China,
Abstract
Effect of MDSC-targeted TFF2-MSA with PD-1 blockade therapy in advanced gastric cancer models.Org: Columbia University Medical Center, Tonix Pharmaceuticals, Columbia University - Mailman School of Public Health,
Abstract
Immune therapy related adverse events in metastatic non-small cell lung carcinoma patients at a rural academic center.Org: Brody School of Medicine at East Carolina University, ECU Health,
Abstract
Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,
Abstract
Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction measurement by ultrasound.Org: Chang Gung Memorial Hospital at Taipei, Chang Gung University Medical College, Chang Gung Memorial Hospital, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL,
Abstract
Evaluation of immune related adverse events following extended interval dosing of immune checkpoint inhibitors.Org: Gundersen Health System, La Crosse, WI, Gundersen Clinic Ltd,
Abstract
Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.Org: University of Michigan, Fred Hutchinson Cancer Research Center, Beaumont Health, University of Michigan Health Management Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,
Abstract
Patient characteristics and treatment patterns in BRAF-mutated unresectable or metastatic melanoma in the United States: A snapshot from real-world data.Org: Pfizer Inc., London, United Kingdom, Kirkland, QC, Canada, Pfizer, Inc., Cambridge, MA, Pfizer,
Abstract
Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.Org: Federal University of Minas Gerais - UFMG, Princess Margaret Hospital, Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto,
Abstract
Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,
Abstract
Neoadjuvant sintilimab combined with chemotherapy in resectable locally advanced non-small cell lung cancer: A retrospective study.Org: Sichuan Cancer Hospital & Institute, Sichuan, Sichuan Cancer Center, Radiation Oncology Key Laboratory of Sichuan Province, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, School of Medicine, Zhejiang University, Hangzhou, China, University of Electronic Science and Technology of China,
Abstract
The evolution of treatment patterns in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) and clinical outcomes: Results of a longitudinal observational cohort study in England.Org: Merck, Health Data Insight CIC, NHS Digital,
Abstract
Improving the care of patients with lung cancer hospitalized with immune checkpoint inhibitor-related pneumonitis: Implementation of a clinical pathway algorithm.Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,
Abstract
Multiple antigen stimulating cellular therapy (MASCT)-I for metastatic urothelial carcinoma (mUC): A multicenter, phase I study (MASCT-I-1001).Org: Sun Yat-sen University Cancer Center Gansu Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China,
Abstract
Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.Org: CAPESESP,
Abstract
Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience.Org: Worcestershire Acute Hospitals NHS Trust, Worcester HIV Vaccine, Wet Midlands,
Abstract
Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: A systematic review of clinical trials.Org: BronxCare Health System, New York Medical College - Saint Michael's Medical Center, Saint Mary's and Saint Clare's Hospital, Mercy Hospital Fort Smith, Arkansas College of Osteopathic Medicine,
Abstract
Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.Org: Mayo Clinic Florida, Mayo Clinic,
Abstract
Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.Org: Federal University of Pará - UFPA, Belem, Brazil, Princess Margaret Hospital, Toronto Allergy and Asthma Centre,
Abstract
Systemic inflammation markers ratio in heavily pretreated NSCLC patients treated with nivolumab.Org: Clinical Hospital Centre Zagreb, Zagreb, Croatia,
Abstract
Effect of immunotherapy cessation without disease progression on outcomes in patients with metastatic non-small cell lung cancer.Org: Mayo Clinic Florida, Jacksonville, Mayo Clinic,
Abstract
Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma.Org: Centre Hospitalier Universitaire Vaudois, Frontier Science Foundation - Hellas, Immune Landscape Laboratory, Centre Thérapies expérimentales, Department of Oncology, CHUV - Centre Hospitalier Universitaire Vaudois,
Abstract
Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression.Org: Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, Division of of Pulmonary Medicine, Abraham Cancer Center, University of Pennsylvania, Philadelphia, PA, Department of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA,
Abstract
Microsatellite instability in sarcomas: Which tests are ideal for diagnosis, and a systematic review.Org: Hospital Israelita Albert Einstein,
Abstract
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.Org: Arnie Charbonneau Cancer Research Institute, University of Calgary, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Alberta, Tom Baker Cancer Centre,
Abstract
CAROLINE study: Incidence and characterization of melanoma in French Polynesia.Org: Gustave Roussy Institute, Hopital Europeean Georges Pompidou, Universite Paris Cite, CHU Poitiers - Jean Bernard Hôpital, Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae,
Abstract
Granular analysis of individual immune-related gene expression in a randomized phase I/II study of the oncolytic adenovirus, ONCOS-102, in combination with pemetrexed/cisplatin (P/C) in patients (pts) with unresectable malignant pleural mesothelioma (MPM).Org: Targovax ASA, Hospital Universitari Vall d´Hebron and Vall d´Hebron Institute of Oncology (VHIO), CHU Rennes – Hôpital Pontchaillou, Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Clinical Research Unit,
Abstract
Real-life use of cabozantinib as front-line therapy in metastatic renal cell carcinoma: The CabFRONT (Meet-URO 24) study.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Health Sciences, University of Florence, Florence, Italy, Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS, Padua, Italy, Oncology Unit, Foundation Casa Sollievo della Sofferenza IRCCS, San Giovanni Rotondo, Italy,